Evidation Health, a San Mateo, California-based health analytics data company, landed $153 million in a Series E funding round led by OMERS Growth Equity and Kaiser Permanente Group Trust. McKesson Ventures and B Capital Group also participated.

This comes less than a year after the company closed its $45 million Series D round.

WHAT IT DOES

Evidation is able to combine real-world patient data from multiple sources, including Apple Health, Fitbit, Epic and Dexcom and in turn assess care or specific intervention from its payer, pharma and health systems clients.

The company’s app and platform, named Achievement, is positioned as a research tool that allows patients to add their real-world health data for studies. Evidation has worked with a number of research partners including the American College of Cardiology and Apple.

WHAT IT’S FOR

The company is planning to use the new funds to expand its virtual health capabilities. According to the release, the new program will personalize insights and help patients manage their own care.  

“Achievement has made it possible to rapidly understand health and therapeutic impact with speed and rigor at scale,” Deborah Kilpatrick, Ph.D., co-CEO and executive chair at Evidation, said in a statement.

“The next era of Evidation will transform how individuals interact with the ecosystem of care by providing anyone with evidence-supported guidance and actionable tools to better understand and improve their health. We are now the first company that can help digital health and biopharma companies generate evidence about their treatments, and then enable individuals to use that evidence to take actions to manage their health.”

MARKET SNAPSHOT

Using real-world data for research has become a hot topic in digital health. Picnic Health is also working in the space of patient generated data. The company’s main mission is to help patients access and share their medical records.

More recently it teamed up with Roche subsidiary Genetech in an initiative that would allow the researchers to have access to its set of de-identified patient records in order to gain insights about certain diseases and treatments. Patients must first consent to having their data used as part of the research.

Flatiron Health, which was acquired by Roche for $1.8 billion, created an oncology EHR that used real-world data for research.